TAR-200 plus cetrelimab versus cetrelimab monotherapy as neoadjuvant therapy in patients with muscle-invasive bladder cancer who are ineligible for or decline neoadjuvant cisplatin-based chemotherapy (SunRISe-4): interim analysis of a randomised, open-label phase 2 trial

por | Ene 1, 2025 | Publicaciones - B-11 | 0 Comentarios

Necchi, A; Guerrero-Ramos, F; Crispen, PL; Herrera-Imbroda, B; Garje, R; Powles, T; Peyton, CC; Pradere, B; Ku, JH; Shore, N; Bögemann, M; Preston, MA; Xylinas, E; Llano, CSD; Hasan, M; Stitou, H; Bhanvadia, S; Sweiti, H; Psutka, S – 2025 – 10.1016/S1470-2045(25)00358-4